We synthesized new indolylarylsulfone (IAS) derivatives carrying a heterocyclic tail at the indole-2-carboxamide nitrogen as potential anti-HIV/AIDS agents. Several new IASs yielded EC 50 values <1.0 nM against the HIV-1 WT and mutant strains in MT-4 cells. The enantiomer (R)-11 proved to be exceptionally potent against the whole viral panel; in the RT screening assay it was remarkably superior to NVP and EFV and comparable to ETV. The binding poses were consistent with the one previously described for the IAS NNRTIs. Docking studies showed that the methyl group of the (R)-11 pointed towards the cleft created by the K103N mutation, differently from the corresponding group of (S)-11. By calculating the solvent accessible surface, we observed that the exposed area of the RT in complex with (S)-11 was larger than the area of the (R)-11 complex. Compounds 6 and 16 and the enantiomer (R)-11 represent novel robust lead compounds of the IAS class.
INTRODUCTION

Human immunodeficiency virus type 1 (HIV-
1
3,4
The clinical treatment for HIV/AIDS takes advantage of the multiple benefits of the antiretroviral therapy (ART), also known as active antiretroviral therapy (HAART). ART abides of two or at least three antiretroviral drugs from different drug classes. The life-saving ART regimens suppress the HIV-1 replication and slow down the progression of viral infection, particularly in early stages of the disease, maintaining plasma viremia below the detection level in most patients undergoing treatment for at least six months.
5
Nevirapine (NVP), Delavirdine (DLV) and Efavirenz (EFV) are first-generation NNRTIs; it is recognized that such agents rapidly develop drug resistance; in particular the K103N and Y181C mutations are prevalent from clinical HIV-1 isolates. 6 Newer NNRTIs, Etravirine (ETV) and Rilpivirine (RPV) were approved for use in drug combination to manage treatment-experienced HIV-1 infected people, and naïve and adult patients, respectively. 7 However, despite a significant progress, drug resistance and adverse effects continue to emerge in ART receiving patients. 8 These data underlines the need of new antiretroviral agents with improved and tolerability resistance profiles. Table 1 ).
In the indolylarylsulfone (IAS) HIV-1 NNRTI class, the two methyl groups at positions 3' and 5' of the 3-phenylsulfonyl moiety proved to ensure a broad spectrum of activity against mutant HIV-1 strains.
The indole-2-carboxamide demonstrated to tolerate a wide diversity of substituents (natural or unnatural amino acids, hydroxyethyl moiety, Mannich bases) to provide IAS analogues with remarkable antiviral potency.
9
The introduction of an additional aromatic nucleus to the parent compound resulted in NNRTIs with broad spectrum of activity against the mutant HIV-1 strains. 10 Accordingly, IAS derivatives bearing an additional (third) cyclic moiety linked through 1C or 2C spacer group the 2-carboxamide nitrogen (1) (2) (3) showed potent antiretroviral activity. 11, 12 Therefore, we planned the synthesis of new inhibitors that would address this drug design strategy. The new IAS derivatives 4-20 showed potent HIV-1 inhibitory activity in the low nanomolar range (Chart 1 and Table 1 ). Direct enantioseparation of the racemic mixture (R,S)-11 was performed by enantioselective HPLC using the cellulose derived Chiralcel OD chiral stationary phase (CSP) and the binary mixture nhexane-ethanol 50:50 as a mobile phase ( Figure 1A ). The optimized analytical enantioselective method was scaled-up to a semi-preparative level to obtain mg-amounts of the pure enantiomers for the screening. The stereochemical characterization of (S)-11 and (R)-11 was performed by circular dichroism (CD) correlation method using the (R)-3 and (S)-3 pure enantiomers as reference samples ( Figure 1B and 1C) . The (R) configuration was empirically assigned to the more retained enantiomer (S)-11 on the Chiralcel OD CSP, and the (S) configuration to the less retained enantiomer (R)-11.
RESULTS AND DISCUSSION
Independently on the substituent at the nitrogen atom at the position 2 of the indole, a large proportion (Table 1 ). The majority of the new IASs were superior to the reference drugs NVP, EFV, and AZT. Unless 8, the new IAS derivatives showed cytotoxic concentrations (EC 50 values) >20000 nM. With the exception of 7, 9 and 14, the new derivatives showed selectivity indexes (SI = CC 50 /EC 50 ratio) >20000. Derivative 16, showed the highest SI value (SI >282218) within the series; it was superior to NVP, EVF and AZT and comparable the reference IASs 1-3. As expected for NNRTI, 14 compounds did not show inhibitory activity for HIV-2.
We initially synthesized the 4-pyridinyl derivative 4 by expelling the methylene spacer group.
Compound 4 proved to be a potent inhibitor of the HIV-1 NL4-3 WT and K103N mutant strains (EC 50 = 0.23 nM), but it was weakly effective against the K103N-Y181C double mutant strain ( Table 2) .
Extrusion of the nitrogen atom from the pyridinyl ring of 4 resulted in an equipotent inhibitor of the = 132 nM, being >28-and >2.5-fold more potent than NVP and EFV, respectively, and 16-fold superior to IAS 1. Shifting the substituents of the 3-phenylsulfonyl moiety from 3',5' to 2',6' positions retained the antiretroviral activity only in the case of the 2',6'-dichloro derivatives 8 and 10 (compare with 7 and 9).
The replacement of the phenyl group of 3 with a pyridinyl ring to obtain 11 resulted in a general improvement of the antiviral activity. Racemate 11 were found to be 3-fold more potent than 3 as inhibitor of the NL4-3 WT strain (EC 50 = 0.2 nM). Against the Y181C, L100I and K103N-Y181C mutant strains IAS 11 was respectively 8-and 6-and 3-times superior to 3. Such results prompted the separation at semi-preparative level of the racemic mixture 11 into the pure enantiomers (S)-11 and (R)-11 by chiral HPLC ( Table 3 ). The enantiomers proved to be equipotent (EC 50 = 0.2 nM) against the NL4-3 WT strain, and showed quite similar cytotoxic concentrations (data not shown). On the contrary, (Table 6 ). Both compounds showed no activity against HIV-2 ROD in PBMC (data not shown). Compound concentration (IC 50 , nM) required to inhibit by 50% the RT activity of the indicated strain.
c The recombinant HIV-1 RT carrying the Y181I mutation was comparable to the Y181C substitution in terms of drug resistance, from an enzymological point of view.
d
Data of R,S racemic mixture.
e Lit. 
MOLECULAR MODELING
In order to gain further insight on the binding mode of the reported compounds, a series of docking experiments was carried out following a previously reported methodology. The docking experiments were also repeated versus the K103N mutated RT. In this case, we observed that the binding mode of the majority of the compounds was not affected by the K103N mutation. However, the (S)-and (R)-enantiomers showed some significant differences in their binding mode: while the methyl group of the (R)-enantiomer pointed toward the cleft created by the K103N mutation, sealing the binding pocket and reducing the solvent-accessible surface, the corresponding group of the (S)-enantiomer left the pocket more exposed to the solvent. (Figure 3 ) It should be noted that this observation is in accordance with the proposed mechanism of resistance related with the K103N mutation based on a binding kinetic effect.
16,17
To gain more information regarding the binding mode of these compounds, we performed a series of molecular dynamic simulations of both the WT and K103N mutated RT, in complex with 35 and 36. In agreement with the biological data, the simulations into the WT RT produced very similar results for the two enantiomers. Furthermore, both complexes showed a significant stability during the whole simulation time.
In the case of the K103N RT/(S)-11 and K103N RT/(R)-11 complexes, the molecular dynamics trajectories analyses also showed that both complexes were stable during the whole simulation time.
This is in accordance with the kinetic hypothesis of resistance, mentioned above. 16, 17 Following this reasoning, the solvation effect on the protein/ligand complexes should play a major role in the binding kinetic of (S)-11 and (R)-11 to K103N RT. Thus, to investigate this point, we calculated the solvent accessible surface area (SASA) 18 of the binding site for both complexes during the simulations time.
Interestingly, we observed a significant difference between both enantiomers; SASA of the receptor in (Table 7) . (458.98)) C, H, Cl, N, S. 
5-Chloro-3-((2,6-dimethylphenyl)sulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide (9). It was synthesized as
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide (10
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide (11)
.
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-2-yl)ethyl)-1H-indole-2-carboxamide (12). It was synthesized as
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-3-yl)ethyl)-1H-indole-2-carboxamide (13)
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(N'-(pyridin-4-yl)amino)-1H-indole-2-carbohydrazide (14
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-(N'-methylamino-N'-phenyl)-1H-indole-2-carbohydrazide (15
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(furan-2-ylmethyl)-1H-indole-2-carboxamide (16).
It was synthesized as
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(thiophen-2-ylmethyl)-1H-indole-2-carboxamide (17
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(thiophen-2-yl)ethyl)-1H-indole-2-carboxamide (18
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-(thiophen-2-yl)ethyl)-1H-indole-2-
carboxamide (19 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-indole-2-carboxamide (20
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxamide (8). It was synthesized as
7 starting from 30 (yield 32%). Spectral and chemico-physical data were in agreement with those previously reported. (25) . To a mixture of NaH (60 % in mineral oil) (220 mg, 5 mmol) in anhydrous DMF (7 mL) was added 24 (450 mg, 2.3 mmol) and the reaction mixture was stirred at 25 °C for 10 minutes. 1,2-Bis-(2,6-dimethylphenyl)disulfide (700 mg, 2.5 mmol) was added and the reaction mixture was stirred at 100 °C overnight. The reaction mixture was diluted with water, made acid with 6N HCl, and extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave the crude acid that was used without further purification.
General Procedure for the Preparation of Derivatives 25 and 26. Example: 5-Chloro-3-((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylic acid
5-Chloro-3-((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylic acid (26). It was synthesized as
25 starting from 24 and 1,2-bis-(2,6-dichlorophenyl)disulfide. It was used as crude product without further purification. (27) . Thionyl chloride (1.8 g, 1.07 mL, 15 (23) . Lithium hydroxide monohydrate (50 mg, 1.2 mmol) was added to a solution of 27 (180 mg, 0.4 mmol) in THF (5 mL) and water (5 mL).
General Procedure for the Preparation of Derivatives 27 and 28. Example: Ethyl 5-chloro-3-((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylate
Ethyl 5-chloro-3-((2,6-dichlorophenyl)thio)-1H-indole-2-carboxylate (28)
Ethyl 5-chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxylate (30
Then the reaction mixture was stirred at room temperature for 48 h. After dilution with water, the Research and Development Center). Proteins were expressed in E. coli and purified as described. Then, a serie of four molecular dynamic equilibrations were performed. The first simulation was run for 12 ps at a temperature of 10 °K in the NVT ensemble with proteins and ligands heavy atoms restrained with force constant of 50 kcal/mol per Å 2 . Another 12 ps simulation was performed with the same harmonic restraints; this time in the NPT ensemble. A 24-ps simulation followed with the temperature raised to performed at 300 °K in the NPT ensemble and the force constant retained.
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxylic acid (23)
Finally, a 24-ps simulation was performed at 300 °K in the NPT ensemble with all restraints removed. The analysis started with 0% of A, which linearly increased up to 70% in 10 min and then slowly up to 98% in 15 min. The flow rate was 0.2 mL min -1 and injection volume was 5 μL. The instrument operated in positive mode with detector 1850 V, drying gas pressure 25.0 psi, desolvation temperature 300 °C, nebulizing gas 40 psi, needle 5000 V and shield 600 V. Nitrogen was used as nebulizer gas and drying gas. Collision induced dissociation was performed using Argon as the collision gas at a pressure of 1.8 mTorr in the collision cell. The transitions as well as the capillary voltage and the collision energy used for compound are summarized in Table 8 . well of the acceptor plate were added 300 μL of 50% DMSO -phosphate buffer solution. The experiments were carried out in three plates on different days. The sandwich was incubated for 5 h at room temperature under gentle shaking. After incubation, the plates were separated, and samples were taken from both receiver and donor sides and analysed using LC with UV detection at 254 nm. LC analysis were performed with a Perkin-Elmer series 200 provided with an UV detector (Perkin-Elmer 785A, UV/vis Detector). Chromatographic separations were achieved using a Kinetix C18 column (Phenomenex, 100 x 4.6 mm, 2.6 μm particle size at a flow rate of 0.6 mL min -1 and a mobile phase of 6:4 ACN-water. The reaction mixtures were centrifuged for 15 min at 10000 rpm, and the parent drug and its metabolites were determined by LC-UV-MS. The chromatographic analysis was performed as above reported. The percentage of unmetabolized compound was calculated using reference solutions. The experiments were performed in triplicate and the metabolic behaviour was predicted by means of Metasite software.
Plasma Stability Assay. To determine the enzymatic stability, pooled human plasma (750 µL), phosphate buffer (pH 7.4, 700 µL), and 50 µL of 3.0 mM solution of (R)-11 in DMSO (final concentration 100 µM) were mixed in a test tube. The mixture was incubated at 37 °C. At the time points of 0 h and 24 h aliquots of a 150 µL were removed, mixed with 600 µL of cold ACN and centrifuged at 5000 rpm for 15 min. The supernatant was removed and analysed by HPLC. The stability was checked by HPLC with UV-MS detector as above reported.
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